Hyfinity Investments

Jianda Biopharmaceuticals is a clinical-stage vaccine research and development company that develops innovative vaccines and new adjuvants.

ZD Medical specializes in developing advanced medical imaging technologies. Its flagship product is a non-invasive, early-detection system using phase variance optical coherence tomography, capable of simultaneously identifying macular degeneration and retinal microvascular proliferation caused by diabetes.

Delova Biotech is a company dedicated to advancing pain treatment through the development of non-opioid analgesics. Leveraging extensive research and development experience, Delova Biotech focuses on enhancing existing drugs and creating innovative new analgesics in both China and the United States. The company employs advanced technology platforms, including long-acting injection technology, topical transdermal formulations, and nano-delivery systems, to improve drug efficacy. Additionally, Delova Biotech specializes in prodrug modification and enhancing solubility for insoluble drugs, aiming to deliver superior quality medications that enhance the quality of life for patients experiencing pain.

DPM Digital Precision Medicine specializes in the development of advanced medical equipment and innovative technology, particularly in the field of intraoperative molecular imaging. The company focuses on creating high-sensitivity and high-definition imaging solutions that enhance surgical navigation during procedures. By prioritizing research and development, DPM Digital Precision Medicine aims to deliver easy-to-operate imaging products that improve the precision and effectiveness of surgical interventions, catering to the needs of medical professionals.

Nuoyimeier is a developer of implantable consumables.

Immunowake is a biotechnology company specializing in developing new therapies for cancer patients who do not respond to existing immunotherapies. Its focus lies in harnessing the body's immune system to identify and eliminate cancer cells, with a particular emphasis on generating safer and more effective bispecific antibodies through its universal cancer vaccine.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, leveraging a deep understanding of disease biology and pharmacology to address various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed aims to provide healthcare professionals with more effective treatment options by building a robust translational platform that integrates advanced expertise and efficient execution capabilities in drug development.

Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Cargene uses proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases.

Carcell BioPharma is a pre-clinical biotechnology company focused on developing innovative cell and gene therapy products. The company specializes in biopharmaceutical platforms aimed at advancing next-generation therapies, particularly through engineered red blood cells for immune regulation and non-viral vector gene delivery utilizing lipid nanoparticles. Carcell BioPharma's unique cross-border business model supports its commitment to accelerating the discovery and development of these cutting-edge therapies, addressing critical needs in the field of medicine.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Hexaell Biotechnology Co., Ltd is an innovative start-up focused on developing advanced solutions for severe liver diseases through stem cell technology and bio-artificial organs. The company has licensed cutting-edge technologies, specifically iHep and HiHep, from the Chinese Academy of Sciences, which are foundational to its approach in creating medical devices aimed at replacing liver function and treating liver failure. Hexaell's research and development efforts have led to promising clinical applications, including successful pilot studies involving six liver failure patients at leading hepatopathy centers in China. By harnessing cell differentiation and production technology, Hexaell aims to provide patients with new and effective treatment options for liver-related health challenges.

iPharmacare is a provider of medical and health administration services, specializing in clinically rational drug use support and monitoring management. The company offers a comprehensive set of solutions designed to enhance prescription decisions through the analysis of real-world clinical prescription data. By employing the PDCA cycle management model, iPharmacare aims to ensure that medical institutions can make informed and effective prescribing choices, ultimately improving patient care and safety.